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Pharmacist and physician 
in health services
Optimal pharmacotherapy 
through close cooperation of physician 
and pharmaclst
During the last few decades an overwhelming de­
velopment in medicine and pharmaceutics has 
taken place. Many new and highly effective med- 
icaments have been introduced for the treatment 
of infections, mental diseases, etc. These medico- 
pharmaceutical advances have had and are still 
having a gfeat influence on society, our culture and 
the sciences (Lasagna, 1969).
The avaiiability of very potent drugs which may 
be used to the benefit of the patiënt, places a great 
responsibility on the physician who prescribes such 
drugs and on the pharmacist who dispenses them. 
Mankind is challenged not only by the extensive 
use of chemicals as flavours in food, insecticides on 
fruit, and environmental pollutants, but also by 
the inappropriate use of drugs, especially psycho- 
tropic drugs.
Hlstoricai development of specialists 
on medicaments
It is obvious that those who deal with the applica­
tion of drugs should share their specialist knowl- 
edge to ensure rational pharmacotherapy.
In Galen’s time the exercise of the medicai prö- 
fession and the pharmaceutical profession were 
still in the same hands. Except for Extr. bella- 
donnae and a number of poisonous plants, few 
potent medicines were available.
Gradually a separation of the medicai and pharma­
ceutical profession took place, for which increase 
in specific knowledge was mainly résponsible. Ad­
vances in anatomy and physiology were made, 
while new methods were added to the knowledge 
of compounding. In the year 1240, Frederic of 
Hohenstaufen, King of Naples and Sicily, decreed 
by law that medicine and pharmacy should no 
longer be practised by the same individual. For 
ethical reasons there should be no financial con- 
netfion between the physician and the pharmacist. 
In'the Nêtherlanais, the remains of the situation 
existing from before the Middle Ages may still 
be fbundl in the so-called “pharmacy-licensed phy- 
siciins”. Although it is obvious that individuals 
with highly specialized academic training are nec- 
essary in order to fulfil their task in the Health 
Services adequately, it is also necessary that they 
cooperate. »
macy is one of the reasons for the insufficiënt con-
i tact that exists between physicians and pharma- 
' cists. As a result of the tremendous development 
of purely medicai sciences, the tendency exists with 
the physician to focus all attention on diagnosis. 
Once the diagnosis is made, prescription-writing 
is a matter of seconds.
The pharmacist is too occupied with the quality of 
the product and he tends to ignore its pharma- 
cology and the patiënt. But it is not yet too late to 
share the knowledge of physician and pharmacist 
for the benefit of the individual patiënt and the 
health of mankind.
Drug and medicament
Many drugs are available for all kinds of illnesses 
and diseases. Not only that but for each specific 
syndrome various related drugs are at our disposal.
A large number of closely related barbiturates are 
available for use in a case of sleeplessness, and • 
j several antihistamines in a case of hay fever. Sev- 
; eral of these drugs are marketed under a variety of 
; proprietary names (see for example Table I). This 
variety may be a source of confusion, and it could 
therefore be easier to use the chemical name of a 
drug. However, the rules for the chemical name 
are not unambiguous while the chemical name is. 
oftèn complicated, very long and bearing no re- 
lation to pharmacological action. Nonproprietary 
names or generic names, adopted by the World 
Health Organization, therefore fulfil a purpose 
(see Table I).
It should be realized that a chemical is in general 
not given as such to the patiënt. For instance a 
bottle containing 20 grams of acetylsalicylic acid 
is not dispensed; this analgesic is given in divided 
doses in a particular dosage form. The dosage form 
—tablet, capsule, suppository—not only consists of 
the drug proper but also of certain pharmaceutical 
additives, colouring matter, etc.
It is logical to restrict the word ‘'medicament’’ or 
“medicine” to the final product that the patiënt 
receives, whereas the Wörd “drug” or “pharma- 
con” is reserved for the active principle that it con- 
tains. The drug should be identified by its generic 
name and the medicament or drug product by its 
proprietary name or the number assigned to it by 
the manufacturer.
There was a time when pharmacist and physician were one and the same person, but since 
the Middle Ages the professions have drifted apart Now it is time to consider bringing 
them closer together. The pharmacist has much to offer the physician in deciding on a 
therapéutic policy, as Professor van Rossum shows.
The separate development of medicine and phar-
Table I Some synonyms of drugs (Marler, 1967). Pity thepoor prescriber!
chemical name 
acetylsalicylic acid
..  chemical name " " "  '
2-methyl-2-propyl-1,3- 
propanediol dicarbamate
chemical name '  
2-diphenyl-2-benzhydroxy- 
N, N>dimethylethylamine 
hydrochloride
Chemical name 
2-chioro-10 (3-di- 
methylaminopropyl) 
phenothiazine
generic name " generic name ~ " generic name .......... generic name
acetosal ' meprobamate diphenhydramine chlorpromazine
proprietary name ‘ —  proprietary name proprietary namis proprietary name
acesal meprotan benzhydramine aminasin
acetosal procalmadiol anautine aminazine
acetan andasifr'... . dimedrd HL-B746
acetasal aheural PM-255 RP-4560
aceticyl aneurol S-51 SKF-2601-A
acetilum aneuxral alledryl ampliactll
acetol apasil allergical amplictil
acetophen arpon allergin chlorbromasin
acetosal in artolon allurgina chlorderazin
acetylin atraxin amidryl fenactil
acytosal biöbamate bsigodryl hibanil
A SA calmiren benaarin hibemal
acetylon cirpon : benadryl hibemol
acetylsal cirponyl benapone klórpromex
acidulatum cyrpon benodine largactil
acylpyrin ecuanil dermistina largactyl
aspergum edenal desentol megaphen
ascriptin epikur dibendrin novomazina
aspirgran equanil dihidral phenathyl
aspirin equtnil dimedryl plegomazin
aspro gagexyl ibiodral propaphen
asteric harmonin nausea propaphenin
darosal hoibamate restamin prozll
ecotrin madiol rigidil thorazene
emocin mepantin rigidyl thorazine
empirin mepavlon syritedrll torazina
enterosarine
In the hospital th e  climate may b e  present for 
fertile cooperation between different specialists and 
the hospital pharmacist. In sèveral large hospitals 
in the United States, pharmacists specialize for 
their C onsulting  role w ith  respect to  therapy in  
internal medicine, paediatrics, psychiatry, etc. They 
apply their special pharmaceutical knowledge o f  
pharmacokinetics or biopharmaceutics for a rational 
pharmacotherapy. These clinical pharmacists are 
patient-oriented, even if they do not in fact treat 
patients.
The difference between clinical pharmacology and 
clinical pharmacy lies in the fact that the clinical 
pharmacologist treats patients and is concerned 
with the actions of the drug in the patiënt, where- 
as the clinical pharmacist advises the clinician with 
respect to the choice of medicament, the dose, the 
dosage form and the dosage. regimen, while the 
clinician remains responsible for his patiënt and 
has to judge the effect. It has been shown that close 
contact between the clinician, his nursing staff and 
the hospital pharmacist considerably improves 
therapy and leads to the correction of unwarranted 
therapeutic habits.
During the last few years a great number of ar- 
1';.ijs ' ’ ' i w r;i:e- on the subject of clinica’ 
pnarmacy. It seems that this way of cooperation. 
leads to optimal pharmacotherapy in the hospital.
The general pharmacist is in control of prescrip- 
tions and may bring errors with respect to the 
prescribed drug, the dose and the dosage regimen 
directly to the attention of the physician. How- 
ever, the physician is not likely to learn from his 
errors if he receives them during a very crowded 
consultation session. Furthermore, prescriptions 
that could be improved but are not wrong as such, 
are not brought to his attention at all.
Far better communication may be established in 
the form of pharmaco-therapy conferences, in 
which several physicians and pharmacists partici- 
pate. In association with the Institute of General 
' Physicians, our Department of Pharmacology has 
initiated such conferences, apparently with great 
success.
In the following paragraphs, specific information 
that may be contributed by the pharmacist will be 
discussed in some detail.
t  ( m i n )
Figure 1
a) Plasma concentration curve of acetylsalicylic acid 
and its metabolite salicylic acid following ingestion 
of an aqueous solution. Even in this case where the 
rate of absorption of acetylsalicylic acid is high, the 
metabolite is more important than the parent pro­
duct. If the drug had been given as a tablet, prac- 
tically no parent product would have been detected. 
Redrawn after data from Roland et al., 1969.
Various medicaments, each containing the same 
amount of a drug, may differ in pharmacological 
potency as a result of a different dosage form 
(potion, tablet, capsule, powder, suppository, etc.) 
and also because different inanufacturers may use 
different pharmaceutical additives, different crystal 
form and size of the drug, and different methods 
of compounding.
Various medicaments, containing thé same drug, 
are not necessarily equipotent; for instance, the 
rate of absorption and the total amount of the 
drug that ultimately becomes absorbed may vary 
considerably. If a drug is given in solution the 
rate of absorption is in general reasonably good, 
but absorption may greatly be delayed if an enteric 
coated dragée is given. This factor is more impor­
tant for drugs that are rapidly metabolized in the 
body. For instance, acetylsalicylic acid (t 1/2 = 2 0  
min.) is rapidly metabolized in the body into sali­
cylic acid (t 1/2 =  ca. 6 h .), while the former is 1 
more potent analgesic than the latter. Concentra- 
tion-time curves of acetylsalicylic acid and its meta­
bolite are given in Figure 1 a. So acetylsalicylic
ad<J should preferably be given as a calcium or 
spdium salt in the form of a powder or tablet, while 
this powder or tablet should be dissolved in water 
just before o ral intake. Enteric coated preparations 
ace ó f  nó us'e (sée Figure 1 b). The total salicylate 
concentration following intake of a solution of 
'acetylsalicylic acid is abóut 80 mg/1. within one 
hour aftèr administration. Following ingestion of 
enteric coated tablets, the maximum—less than 40 
mg/l.—is reached after four hours.
Knowledge of the irifluénce on biological avail- 
ability of various factors in compounding is still 
veiy scarce. Some general conclusions may, how- 
ever, be drawn with respect to additives, etc. The 
relevant information on the drug product should 
be available to the Consulting pharmacist, so that 
he can judge which product is to be preferred. If 
such information is not accessible, he had better 
attend to his own compounding.
In general, drugs produce their effects as a result 
of the interaction of drug molecules with specific 
receptors somewhere in the body. The concentra­
tion of the drug in the direct environment of the 
receptor determines the degree of receptor occu- 
pation and hence the intensity of the pharmacolog­
ical effect. The drug concentration in the direct 
environment of the receptors depends on the con­
centration of the drug in the blood plasma.
The concentration in the blood plasma is a time- 
dependent function of the dose. The rate of ab­
sorption, distribution and elimination mainly de­
termines the shape of the plasma concentration 
curve. The time the drug persists in the body large- 
ly depends on the volume of distribution and the 
total clearance or elimination. Under certain con- 
ditions the biological half-life is a good measure 
of the time the drug remains in the body. It is ob- 
vious that information on the biological half-life 
is important for the establishment of the correct 
dosage regimen. Physicians have the tendency to 
administer most drugs three times a day. For drugs
with a long half-life ( t j / 2 > 2 4  h.) this is not 
necessary.
Drugs that belong to the same pharmacological 
class may differ greatly with respect to biological 
half-life. This is for instance the case for sulfon- 
amides. If such drugs are combined one should cal- 
culate on differences in half-life. The well-known 
trisulfa based on a ratio of sulfadimidine: sulfa- 
diazine: sulfamerazine = 1 : 1 : 1  is on the basis 
of kinetic data not correct (see Figure 2). After 
chronic administration sulfamerazine will accumu- 
late and will be mainly responsible for the bacterio- 
static effect of the combination.
The hospital pharmacist in cooperation with the 
clinician is in a position to gath~r information on 
the pharmacokinetics of drugs. It is hoped that 
kinetic data on the older, generally accepted drugs 
will become available also.
Identification of medicaments is o f vital impor- 
tance to the correct use of drugs. The patiënt, as 
well as the physician, should be able to recognize
Time, hours
b) Plasma concentration curves of acetylsalicylic acid 
following ingestion of a solution (o o o) ancj Qf en„ 
teric coated tablets (eoa). |t is evident from the 
curves that the biological availability of the tablets 
is only a fraction of that of the solution. The value 
of enteric coated tablets of this drug is highly ques- 
tionable. Redrawn after Leonards and Levy, 1965.
time IhJ
Figure 2
Plasma concentration curves calcutated following 
chronic administration of a trisulfa according to a 
dosage-regimen with a starting dose of 6 tablets of 
0.5 g. and a maintenance dose of 2 tablets 6-hourly. 
The level of sulfadimidine falls off, that of sulfadiazine 
is maintained, but that of sulfamerazine incrgases con- 
siderably.
When drugs are combined the pharmacokinetic data
should be taken into account also.
a medicine immediately. For this purpose the so- 
called unit-dose system has great advantage. Each 
dosage form, tablet, capsule, etc., is separately pack- 
ed and labelled.
The various manufacturers of medicaments should 
adopt a Standard system showing on the label the 
proprietary name of the medicament, the generic 
name of the active principle and the dose, e.g.:
BUTAZOLIDIN® tablets 
Phenylbutazone 200 mg.
CIBA-GEIGY Limited
The unit-dose or identi-dose system has the ad­
vantage that the physician remains free to prescribe 
the desired number of dose units, while the med- 
icines keep their identity until the moment of in­
take. A package insert would then be no longer 
necessary. The package insert that accompanies 
packages of a fixed number of dose units contains 
information for the physician, but the physician 
should prescribe a drug only if he is aware of its 
pharmacology and toxicology. It seems unjust that 
he should obtain such information from a package 
insert.
Through close cooperation between dinicians and 
hospital pharmacists and between family physicians 
and community pharmacists, specialist knowledge 
on drugs may be shared and integrated so that 
pharmacotherapy may become more rational. Such 
cooperation is in the interest of the health of man­
kind.
Professor J. M. van Rossum 
Department of Pharmacology 
University of Nijmegen 
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